Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 12,24€(+313,51%). Der Median liegt bei 11,17€(+277,36%).
Kaufen | 14 |
Halten | 17 |
Verkaufen | 4 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Mines D'Or Orbec/Orbec Gold Mines to Attend 121 Mining Investment Conference in London
Chibougamau, Quebec--(Newsfile Corp. - May 9, 2025) - Mines D'Or Orbec/Orbec Gold Mines (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the company is participating in the upcoming 121 Mining Investment Conference in London. John Tait, CEO of Mines D'Or Orbec/Orbec Gold Mines will be presenting about the Company's recent and future planned activities.» Mehr auf newsfilecorp.com
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025. Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it.» Mehr auf businesswire.com
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the “Board”) reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 37,02 Mio | 422,38% |
Bruttoeinkommen | 15,12 Mio | 1.029,54% |
Nettoeinkommen | −27,59 Mio | 65,54% |
EBITDA | −8,65 Mio | 146,88% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 30,01 Mio€ |
Anzahl Aktien | 9,79 Mio |
52 Wochen-Hoch/Tief | 25,56€ - 3,04€ |
Dividenden | Nein |
Beta | 0,33 |
KGV (PE Ratio) | −0,14 |
KGWV (PEG Ratio) | −0,01 |
KBV (PB Ratio) | −1,06 |
KUV (PS Ratio) | 0,40 |
Unternehmensprofil
Name | Bluebird Bio Aktie |
CEO | Andrew Obenshain |
Mitarbeiter | 248 |
Assets entdecken
Shareholder von Bluebird Bio Aktie investieren auch in folgende Assets